ALS: Mitsubishi Tanabe Pharma America Presents Final Results from the Global, Phase 3b MT-1186-A02 Post-marketing Study of RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of final results from the global, multi-center, double-blind, Phase 3b MT-1186-A02 study of oral edaravone in amyotrophic lateral sclerosis (ALS). Final results showed the daily dosing regimen of RADICAVA ORS® (edaravone) did not show superiority to the U.S. Food and Drug Administration (FDA) approved on/off dosing regimen based on the primary endpoint of Combined Assessment of Function and Survival (CAFS) at 48 weeks. Both dosing regimens provided comparable change in ALSFRS-R from baseline to week 48. These findings suggest that the current on/off regimen of RADICAVA ORS is the most appropriate regimen for people living with ALS based on efficacy and safety findings from studies MT-1186-A02 and MCI186-19. ALSFRS-R changes observed at week 48 in Study MT-1186-A02 of RADICAVA ORS were similar to the post hoc assessment of the previous Japanese, Phase 3 Study MCI186-19 of intravenous (IV) RADICAVA® (edaravone).1,2 The MT-1186-A02 study found no new safety concerns and reinforces edaravone as a safe product. The full results are included in a poster presentation at the European Network for a Cure for ALS (ENCALS) 2024 meeting taking place in Stockholm, Sweden.